Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
53,514,204
-
Number of holders
-
30
-
Total 13F shares, excl. options
-
12,460,895
-
Shares change
-
-3,705,477
-
Total reported value, excl. options
-
$13,460,257
-
Value change
-
-$2,676,053
-
Number of buys
-
11
-
Number of sells
-
13
-
Price
-
$1.08
Institutional Holders of Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) as of Q1 2024
As of 31 Mar 2024 Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) had 30 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 12,460,895 shares of stock of the company.
Largest 10 holders included Bain Capital Life Sciences Investors, LLC, FMR LLC, TAKEDA PHARMACEUTICAL CO LTD, RiverVest Venture Management LLC, Rock Springs Capital Management LP, Atlas Venture Life Science Advisors, LLC, VANGUARD GROUP INC, Balyasny Asset Management L.P., RENAISSANCE TECHNOLOGIES LLC, and MORGAN STANLEY.
This table shows 30 institutional shareholders of the security as of 31 Mar 2024.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.